SI-BONE INC
SIBNNASDAQTrading Snapshot
- Day Range
- $21.83 β $22.94
- 52-Week Range
- $11.48 β $21.96
- Volume (shares)
- 950,281
- Avg Volume (shares)
- β
- Shares Outstanding
- 44.8M
- Next Earnings
- 2026-11-02
Fundamentals Snapshot
- Annual Revenue
- $201M
- Last Q Revenue
- $56M
- P/E Ratio
- -64.2
- P/S Ratio
- 4.6x
- EPS (TTM)
- $-0.33
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.6%
SI-BONE INC
SIBNAbout SI-BONE INC
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026
SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that

SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it wil

Is SI-BONE Inc (SIBN) Overvalued After 3.8% Rally? GF Value Says Overvalued
On October 12, 2026, SI-BONE Inc (SIBN) shares rose 3.8% to a current price of $20.10. This movement comes amid a 52-week range that saw a high of $21.89 and a

Analyzing SiBone (NASDAQ:SIBN) & Integer (NYSE:ITGR)
Integer (NYSE: ITGR - Get Free Report) and SiBone (NASDAQ: SIBN - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuati

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyxβ’, Extending Its Compromised Bone Franchise Beyond the Pelvis
FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone

SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript